CUREVAC N.V. news, videos and press releases
For more news please use our advanced search feature.
CUREVAC N.V. - More news...
CUREVAC N.V. - More news...
- EQS-News: CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update
- CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update
- EQS-News: CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024
- CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024
- EQS-News: CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer
- EQS-News: CureVac to Present at the 12th International mRNA Health Conference
- CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer
- CureVac to Present at the 12th International mRNA Health Conference
- EQS-News: CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
- CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
- EQS-News: CureVac’s CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress
- CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress
- EQS-News: CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
- CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
- EQS-News: CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress
- CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress
- EQS-News: CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update
- EQS-News: CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma
- EQS-News: CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board
- CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update
- CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma
- CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board
- EQS-News: CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech
- CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech
- EQS-News: CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities
- EQS-News: GSK and CureVac to Restructure Collaboration into New Licensing Agreement
- GSK and CureVac to Restructure Collaboration into New Licensing Agreement
- CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities
- EQS-News: CureVac Announces Voting Results of General Meeting
- CureVac Announces Voting Results of General Meeting
